Clinical Trials

Esophageal Neoplasms, Stomach Neoplasms

NCT05256225 2026-03-18

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

360 enrolled

Gynecologic

Neoplasms, Endometrial Neoplasms

NCT06136897 2026-03-18

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

BreastGastrointestinalThoracic

35 enrolled 10 charts

Other solid neoplasm

Malignant Solid Neoplasm

NCT06324357 2026-03-18

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Phase 1/2 Recruiting

768 enrolled

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

NCT06625775 2026-03-18

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

392 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT06649331 2026-03-17

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

160 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04253561 2026-03-16

IPATHER

Phase 1 Completed

17 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT04802759 2026-03-16

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1/2 Recruiting

316 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05132582 2026-03-16

HER2CLIMB-05

654 enrolled

Breast Neoplasms

NCT05253651 2026-03-16

MOUNTAINEER-03

400 enrolled

Colorectal Neoplasms

NCT06731478 2026-03-16

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

726 enrolled

Stomach Neoplasms

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06038539 2026-03-13

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Phase 3 Terminated

55 enrolled

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients

NCT04886531 2026-03-12

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

30 enrolled

Breast Neoplasms

NCT07102381 2026-03-12

EmpowHER 208

125 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT03006172 2026-03-11

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

200 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT04285671 2026-03-10

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05733689 2026-03-10

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

Phase 1 Recruiting

20 enrolled

Phase 2/3 Not yet recruiting

Gastroesophageal Adenocarcinoma

NCT07413939 2026-03-10

BREnnA

650 enrolled

HER2-positive Breast Cancer

NCT06764875 2026-03-09

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

840 enrolled

HER2-positive Gastric Cancer

NCT03297606 2026-03-04

CAPTUR

720 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT05672524 2026-03-04

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

37 enrolled

Adenocarcinoma, Rectal Neoplasms

NCT04266249 2026-03-02

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

2,175 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT05325632 2026-03-02

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

53 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07441460 2026-03-02

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

1,800 enrolled

Phase 1 Active not recruiting

Resectable HER2-positive Breast Cancer

NCT03448042 2026-02-27

A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

123 enrolled

Other solid neoplasm

Solid Tumors

NCT03523585 2026-02-27

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

Phase 3 Completed

608 enrolled 17 charts

Phase 3 Active not recruiting

Breast Neoplasms

NCT05152147 2026-02-27

HERIZON-GEA-01

920 enrolled

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

NCT06532006 2026-02-27

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

550 enrolled

Stomach Neoplasms

NCT07053085 2026-02-27

A Study of Surgery and Radiotherapy in People With Breast Cancer

162 enrolled

Breast Neoplasms

NCT07421141 2026-02-27

Opti-HER2

186 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT05593094 2026-02-25

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

210 enrolled

CNS

Brain Neoplasms

NCT07377643 2026-02-25

IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer

540 enrolled

HER2-positive Breast Cancer

NCT03179904 2026-02-24

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

17 enrolled 10 charts

Advanced Breast Carcinoma

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

40 enrolled 67 charts

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT06100874 2026-02-24

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

28 enrolled

Breast Neoplasms

NCT04379596 2026-02-23

DG-03

450 enrolled

Phase 3 Active not recruiting

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT05113251 2026-02-23

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

927 enrolled

Breast Neoplasms

NCT05376878 2026-02-23

An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis

Phase 4 Recruiting

10 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT06016387 2026-02-23

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

30 enrolled

Breast Neoplasms, Meningeal Neoplasms

NCT07193394 2026-02-23

H3RAKLES

20 enrolled

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT04024462 2026-02-20

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

Phase 3 Completed

200 enrolled 16 charts

HER2-positive Early Breast Cancer

NCT01853748 2026-02-19

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

Phase 2 Completed

512 enrolled 28 charts

Breast Neoplasms

NCT01196390 2026-02-18

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Phase 3 Completed

203 enrolled 22 charts